VeriSIM Life
The AI engine Fit Assessment
BetaVeriSIM Life effectively leverages machine learning to enhance drug development, discover patterns in drug interactions, and expand therapeutic options, including drug repurposing.
Blurb
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials.
HQ Location
San Francisco (United States)
Founded
2017
Employees
11 - 50
Total funding raised
$21.66M
Last Funding Event
Series A, $15.00M, January 13, 2022
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Repurposing
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses.